about
Essential role for miR-196a in brown adipogenesis of white fat progenitor cellsTherapeutic vaccines for hypertension and dyslipidemiaAdipose tissue-derived stromal cells as a novel option for regenerative cell therapyCold shock domain protein A represses angiogenesis and lymphangiogenesis via inhibition of serum response elementNovel anti-microbial peptide SR-0379 accelerates wound healing via the PI3 kinase/Akt/mTOR pathwayIdentification of evidence suggestive of an association with peripheral arterial disease at the OSBPL10 locus by genome-wide investigation in the Japanese population.Zyxin mediates actin fiber reorganization in epithelial-mesenchymal transition and contributes to endocardial morphogenesis.Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease.Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes.Involvement of bradykinin and nitric oxide in leptin-mediated glucose uptake in skeletal muscle.Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells.Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell.Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells.Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells.Development of high-throughput functional screening of therapeutic genes, using a hemagglutinating virus of Japan envelope vector.Ubiquitin carboxyl-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-kappaB activation.Development of a novel antimicrobial peptide, AG-30, with angiogenic properties.FHL-2 suppresses VEGF-induced phosphatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1.OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in miceContribution of cardiovascular hypersensitivity to orthostatic hypertension and the extreme dipper phenomenon.ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receptor and inhibits vascular smooth muscle cell growth.HIG1, a novel regulator of mitochondrial γ-secretase, maintains normal mitochondrial function.Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cellsVentricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2.The transcription factors Tbx18 and Wt1 control the epicardial epithelial-mesenchymal transition through bi-directional regulation of Slug in murine primary epicardial cells.Unique remodeling processes after vascular injury in intracranial arteries: analysis using a novel mouse model.A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanismsThe biphasic effects of oxidized-low density lipoprotein on the vasculogenic function of endothelial progenitor cells.Statins and myocardial hypertrophy.Hepatocyte growth factor as potential cardiovascular therapy.Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells.Anti-oxidant gene therapy by NF kappa B decoy oligodeoxynucleotide.Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis.Modification of a novel angiogenic peptide, AG30, for the development of novel therapeutic agentsA Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke.A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction.Modification of decoy oligodeoxynucleotides to achieve the stability and therapeutic efficacy.Nucleic acid drugs for preventing restenosis after coronary revascularization.Development of nucleic acid drugs for neurological disorders.Potential effect of angiotensin II receptor blockade in adipose tissue and bone.
P50
Q21145740-D4421139-3D98-4C83-B6D3-CBCE7593407EQ26859270-FEEF8117-1481-4925-8366-FECD6D92A12CQ28242819-89D90B5A-D619-433D-93DD-77DD286D009CQ28512426-D2217064-DFD6-4028-AE80-60906596E296Q28541612-62478752-B3C9-420C-A35E-8CCFE8B65824Q29417114-D49234FF-B956-4436-9C72-CAAB854C4FA3Q30488540-2395DB91-2BF5-482F-AB81-B33147C6D90FQ30664734-C9FFC201-0A1B-48C5-85B0-C3D025E4F423Q30762712-6C1B34F4-F773-47D5-BE61-470CE82466CDQ31836112-668D317B-99A7-45EB-B8C1-322A28512B84Q32072017-BE9D5990-AB2D-40DB-8597-C30859D06EE4Q32077876-257D3B7F-C28F-4ED5-A153-451F6E70CC20Q33181368-EDEEBEDC-4FD2-493B-BB4C-BAC93C45CA59Q33225144-E38C70DF-5BE7-4640-B24D-E35D3C93AB02Q33239749-1DEAD646-95B9-45AE-BF14-EC1AF72F7A74Q33293798-F0468C10-B15F-4EA8-8DDF-0AEB20BFD5A2Q33328109-3BE9BD9F-CA26-453B-82C2-7D3926CEAB43Q33422807-4B6BF7DC-CFB9-4671-A56F-481A1D7220E3Q33730470-DF356DB0-F4DA-4A7D-8258-AC7F706749B8Q33898566-3BD5615E-51C5-4885-AE79-9E75948F75EEQ33931964-49B28F29-7045-4293-B97B-0162938A0AF2Q34256113-F31C4B48-F388-4C69-BE7F-CD0AF81B00DAQ34334364-63C2A50E-DF98-4A24-972F-FD0D177FED23Q34415806-DDEE81B1-74D7-4AE4-A4EB-6475A802AF84Q34612490-191CDDC3-C482-46BA-9341-3BA915C75FDAQ34661004-93DB3A80-1871-43EC-92F4-8E06FABC9435Q35565491-FA30767B-E265-4044-86C3-65B4D18916E3Q35643408-AB896AA7-AA41-4C5C-959E-72B0F29F653FQ35828423-69BCBDF6-054B-42B7-B3BF-6DF16EE673C8Q36124924-A162EC69-B1E7-43BE-A605-651555BA84ACQ36482246-4BC0A5D3-3CF0-4E38-AFC8-9D454F70437EQ36489264-B7BA79B4-7B9F-4E68-9B55-2F1315817EB9Q37065487-533DEB59-5213-4D9E-9186-21F2DD6C2D66Q37295564-9DA84E74-E0E4-4E6C-961D-1F41934220D8Q37449324-ADF7C46C-C66B-4020-8CD1-91A5A22924A9Q37683865-6697D8A3-DE4F-4D45-AF4F-DCF47746FE78Q38023949-731D3B0F-B7E0-416E-BA3A-C2D7904041D2Q38023951-56F4D9A9-EA74-4838-B8C5-A6D2CE4B186EQ38023952-DCCEE7D3-4995-43E1-80EE-F055A7BEBC73Q38061954-D79BE130-D127-4244-AB57-D9991834FDB1
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hironori Nakagami
@ast
Hironori Nakagami
@en
Hironori Nakagami
@es
Hironori Nakagami
@fr
Hironori Nakagami
@nl
Hironori Nakagami
@sl
type
label
Hironori Nakagami
@ast
Hironori Nakagami
@en
Hironori Nakagami
@es
Hironori Nakagami
@fr
Hironori Nakagami
@nl
Hironori Nakagami
@sl
prefLabel
Hironori Nakagami
@ast
Hironori Nakagami
@en
Hironori Nakagami
@es
Hironori Nakagami
@fr
Hironori Nakagami
@nl
Hironori Nakagami
@sl
P106
P21
P31
P496
0000-0003-4494-3601
P569
2000-01-01T00:00:00Z